Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PT2977 in von Hippel-Lindau Disease-Associated Renal Cell Carcinoma
2018-000125-30Phase 2Active
- Sponsor
- Merck & Co.
- Start
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of belzutifan in von Hippel-Lindau disease-associated renal cell carcinoma (VHL-RCC) and von Hippel–Lindau disease (VHL), sponsored by Merck & Co. Primary endpoint: Overall response rate in VHL disease-associated RCC tumors. Started Mar 2018; status: active.
02
Drugs
belzutifan
03
Conditions
von Hippel-Lindau disease-associated renal cell carcinoma (VHL-RCC)von Hippel–Lindau disease (VHL)
Beyond the preview
Go deeper on 2018-000125-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000125-30.